Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database

Introduction

Older people with Parkinson's disease (PD) are under-represented in clinical trials despite increasing disease burden and complexity. Although opicapone is approved as an adjunct to levodopa, data in elderly populations are limited. This study assessed its real-world safety in the elderly using post-marketing pharmacovigilance data.

Methods